Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - July 8, 2025 706 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MIDAS study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Virtual Mind–Body Fitness Classes Show Unexpected Benefit in People with Cancer December 15, 2023 细针穿刺活检：如何准备和会发生什么 March 8, 2023 When Cancer Spreads to Bone, A Single Dose of Radiation Therapy... May 21, 2019 How I Rebuilt My Self-Image After a Laryngectomy: A Cancer Survivor’s... April 20, 2023 Load more HOT NEWS How People With Cancer Can Benefit From Online Therapy EMA Recommends Granting a Marketing Authorisation for Quizartinib Foodie Friday: Butternut Squash Macaroni Casserole Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in...
